Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX EBITDA Margin

EBITDA as a percentage of revenue.

Novavax, Inc.NASDAQ: NVAX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -0.4%

EBITDA Margin was -0.4% in Q1 FY2026, down 80.5 pp from a year earlier. On a trailing-twelve-month basis it was -7.1%, down 51.3 pp year over year. Over 3 fiscal years it widened by 81.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 7.9% for the fiscal year ending Dec 2026, down from 43.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-0.4%-20.0 pp QoQ
Last fiscal yearDec 2025
43.8%+59.7 pp YoY
LTMMar 2026
-7.1%-51.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-80.5 pp-153.0 pp-72.5 pp
1 year+59.7 pp-35.9 pp-95.6 pp
3 years+81.6 pp-33.2 pp-114.8 pp
5 years+23.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
43.8%
Year-over-year change
+59.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NVAX compares with its peers on the latest reported figures

  • NVAX's LTM Mar 2026 EBITDA Margin of -7.1% is the 2nd highest of the 7 companies compared; the peer median is -77.4%.
  • Its year-over-year change of -51.3 pp is the 5th highest of 7, against a peer median of -34.9 pp.
  • Over three fiscal years its change of +81.6 pp compares with a peer median of -99.6 pp.
NVAX Competitors Peer median
EBITDA Margin for NVAX and competitors
Company Period LTM level YoY 3-year change
EBSEmergent BioSolutions Inc.LTM Mar 202622.8% +10.3 pp+31.0 pp
NVAXNovavax, Inc.LTM Mar 2026-7.1% -51.3 pp+81.6 pp
BNTXBioNTech SELTM Jun 2026-35.6% -34.2 pp-98.4 pp
VALNValneva SELTM Mar 2026-57.7% -35.6 pp+0.1 pp
MRNAModerna, Inc.LTM Sep 2026-97.2% +35.0 pp-184.1 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-148.9% -100.7 pp-100.7 pp
INOInovio Pharmaceuticals, Inc.FY2025-125425.9% -77690.7 pp-122786.1 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding NVAX) -77.4%-34.9 pp-99.6 pp

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue197.58M1.6B556.38M682.16M1.12B
Cost of Revenue0902.64M343.77M202.74M71.14M
Gross Profit197.58M696.31M212.61M479.42M1.05B
Gross Margin100.0%43.5%38.2%70.3%93.7%
Research & Development2.53B1.24B737.5M391.17M336.82M
Selling, General & Admin298.36M488.69M468.95M337.19M150.35M
Operating Expenses1.88B1.34B779.13M728.35M489.07M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
EBITDA(1.68B)(604.71M)(487.39M)(108.04M)492.33M
EBITDA Margin-850.7%-37.8%-87.6%-15.8%43.8%
Operating Income(1.69B)(644.74M)(566.51M)(248.93M)563.27M
Operating Margin-853.6%-40.3%-101.8%-36.5%50.1%
Interest Income00000
Interest Expense21.13M19.88M14.42M20.08M22.55M
Other Income / Expenses(27.96M)(8.91M)23.48M72.32M(121.1M)
Income Before Tax(1.71B)(653.65M)(543.03M)(176.62M)442.17M
Pre-Tax Margin-867.8%-40.9%-97.6%-25.9%39.4%
Income Tax Expense29.22M4.29M2.03M10.88M1.87M
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Net Margin-882.5%-41.1%-98.0%-27.5%39.2%
EPS (Basic)(23.44)(8.42)(5.41)(1.23)2.72
EPS (Diluted)(23.44)(8.42)(5.41)(1.23)2.54
Weighted Avg Shares74.4M78.18M100.77M152.19M161.99M
Weighted Avg Shares (Diluted)74.4M78.18M100.77M152.19M173.1M

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.